Advertisement

PET/CT in Prostate Cancer: What Is New?

  • Alexandra V. Nikaki
  • Vassilios K. Prassopoulos
  • Lida Gogou
Chapter

Abstract

The evolving role of nuclear medicine and particularly of PET/CT over time in prostate cancer is represented by expansion of applications of already used radiopharmaceuticals in everyday clinical practice, by newly utilized radiopharmaceuticals, as well as by the introduction of new imaging modalities such as PET/MRI.

References

  1. 1.
    Fanti S, Minozzi S, Castellucci P et al (2016) PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43(1):55–69CrossRefGoogle Scholar
  2. 2.
    Vag T, Heck MM, Beer AJ et al (2014) Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 24(8):1821–1826CrossRefGoogle Scholar
  3. 3.
    Castellucci P, Ceci F, Graziani T et al (2014) Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-choline PET/CT scan before salvage radiation therapy. J Nucl Med 55(9):1424–1429CrossRefGoogle Scholar
  4. 4.
    von Eyben FE, Kairemo K (2016) Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Ann Nucl Med 30(6):385–392CrossRefGoogle Scholar
  5. 5.
    Schwarzenböck SM, Knieling A, Souvatzoglou M et al (2016) [11C]choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy. Oncotarget 7(39):63747–63757CrossRefGoogle Scholar
  6. 6.
    Chan J, Carver A, Brunt JN et al (2017) Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy. Br J Radiol 90(1071):20160818CrossRefGoogle Scholar
  7. 7.
    Chang JH, Joon DL, Lee ST et al (2011) Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol 99(2):187–192CrossRefGoogle Scholar
  8. 8.
    Umbehr MH, Muntener M, Hany T et al (2013) The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64:106–117CrossRefGoogle Scholar
  9. 9.
    Hofman MS, Iravani A (2017) Gallium-68 prostate-specific membrane antigen PET imaging. PET Clin 12(2):219–234CrossRefGoogle Scholar
  10. 10.
    Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197–209CrossRefGoogle Scholar
  11. 11.
    Marlon Perera M, Nathan Papa N, Daniel Christidis D et al (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70(6):926–937CrossRefGoogle Scholar
  12. 12.
    Schwenck J, Rempp H, Reischl G et al (2017) Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44:92.  https://doi.org/10.1007/s00259-016-3490-6 CrossRefPubMedGoogle Scholar
  13. 13.
    Sörensen J, Owenius R, Lax M, Johansson S (2013) Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging 40(3):394–402CrossRefGoogle Scholar
  14. 14.
    Turkbey B, Mena E, Shih J et al (2014) Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and Histopathologic analysis. Radiology 270(3):849–856CrossRefGoogle Scholar
  15. 15.
    Kairemo K, Rasulova N, Partanen K, Joensuu T (2014) Preliminary clinical experience of trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients. Biomed Res Int 2014:305182CrossRefGoogle Scholar
  16. 16.
    Schuster DM, Nieh PT, Jani AB et al (2014) Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)in-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 191(5):1446–1453CrossRefGoogle Scholar
  17. 17.
    Odewole OA, Tade FI, Nieh PT et al (2016) Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging 43(10):1773–1783CrossRefGoogle Scholar
  18. 18.
    Nanni C, Zanoni L, Pultrone C et al (2016) 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging 43(9):1601–1610CrossRefGoogle Scholar
  19. 19.
    Akin-Akintayo OO, Jani AB, Odewole O et al (2017) Change in salvage radiotherapy management based on guidance with FACBC (fluciclovine) PET/CT in postprostatectomy recurrent prostate cancer. Clin Nucl Med 42(1):e22–e28CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Alexandra V. Nikaki
    • 1
    • 2
  • Vassilios K. Prassopoulos
    • 1
  • Lida Gogou
    • 1
  1. 1.Nuclear Medicine and PET/CT DepartmentHygeia HospitalAthensGreece
  2. 2.Clinical Physiology DepartmentKanta-Hame Central HospitalHameenlinnaFinland

Personalised recommendations